Ana M. Pizarro completed a PhD in Chemistry at the Universidad Autónoma de Madrid in 2004 under the supervision of Prof. C. Navarro-Ranninger, working on trans-platinum drugs. In 2004 she was awarded a Marie Curie Fellowship (EIF) to work in the laboratory of Prof P. J. Sadler FRS at the University of Edinburgh (UK) on new organometallic ruthenium drugs. She moved to the University of Warwick (UK) in 2007 where she focused on how selected metallodrugs (based on ruthenium, osmium and iridium) exert their anticancer effects in tumour cells. In January 2014 she joined IMDEA Nanoscience as a Ramón y Cajal Fellow where she has established her research group. She also coordinates the Cell Culture Unit at IMDEA Nanoscience.
The Potent Oxidant Anticancer Activity of Organoiridium Catalysts, Z. Liu, I. Romero-Canel n, B. Qamar, J.M. Hearn, A. Habtemariam, N.P.E. Barry, A.M. Pizarro, G.J. Clarkson, P.J. Sadler, Angew. Chem. Int. Ed. 2014, 53, 3941 3946.
This work has recently received media attention: http://www.bbc.com/news/uk-england-coventry-warwickshire-26837963.
Cancer Chemistry: Designing New Drugs for Cancer Treatment (Chapter 15) in The Molecular Biology of Cancer. A bridge from Bench to Bedside, 2nd Edition. Ana M. Pizarro and Peter J. Sadler. Editors: Stella Pelengaris and Michael Khan, John Wiley & Sons, Inc (2013), pp. 436-460.
- Activation Mechanisms for Organometallic Anticancer Complexes in Medicinal Organometallic Chemistry (Vol 32), in Topics in Organometallic Chemistry. Ana M. Pizarro, Abraha Habtemariam and Peter J. Sadler. Editors: Gérard Jaouen and Nils Metzler-Nolte, Springer-Verlag, Berlin, Heidelberg, Germany (2010), 21-56.